| Deep brain stimulation targets in epilepsy: systematic review and meta‐analysis of anterior and centromedian thalamic nuclei and hippocampus A Vetkas, A Fomenko, J Germann, C Sarica, C Iorio‐Morin, N Samuel, ... Epilepsia 63 (3), 513-524, 2022 | 75 | 2022 |
| Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta … NN Alrabadi, HM Abushukair, OE Ababneh, SS Syaj, SS Al-Horani, ... Clinical and Translational Oncology 23, 1885-1904, 2021 | 13 | 2021 |
| Genomic and transcriptomic predictors of response to immune checkpoint inhibitors in melanoma patients: a machine learning approach YB Ahmed, AN Al-Bzour, OE Ababneh, HM Abushukair, A Saeed Cancers 14 (22), 5605, 2022 | 5 | 2022 |
| First‐versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis H Abushukair, S Syaj, O Ababneh, A Qarqash, C Schinke, ... American Journal of Hematology 97 (7), 942-950, 2022 | 4 | 2022 |
| Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival S Hamouri, N Alrabadi, S Syaj, H Abushukair, O Ababneh, L Al-Kraimeen, ... Surgery Today, 1-14, 2022 | 4 | 2022 |
| Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance H Abushukair, O Ababneh, S Zaitoun, A Saeed Cancer Treatment and Research Communications 33, 100643, 2022 | 4 | 2022 |
| Management of chronic subdural hematoma: A study from Jordan S Jarrar, MM Al Barbarawi, SS Daoud, QA Samara, AA Qarqash, ... Journal of Taibah University Medical Sciences 17 (6), 1021-1030, 2022 | 3 | 2022 |
| Cancer-Associated Fibroblasts in Gastrointestinal Cancers: Unveiling Their Dynamic Roles in the Tumor Microenvironment NN Al-Bzour, AN Al-Bzour, OE Ababneh, MM Al-Jezawi, A Saeed, ... International Journal of Molecular Sciences 24 (22), 16505, 2023 | 2 | 2023 |
| The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia O Ababneh, H Abushukair, A Qarqash, S Syaj, S Al Hadidi Clinical Hematology International 4 (1), 21-29, 2022 | 2 | 2022 |
| Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up S Al Hadidi, OE Ababneh, CD Schinke, S Thanendrarajan, C Bailey, ... Blood Advances 8 (3), 703-707, 2024 | 1 | 2024 |
| Clinical and radiologic differences between early onset, late onset, and very late onset adult multiple sclerosis M Palathinkara, AN Razzak, OE Ababneh, D Cairns, AZ Obeidat Multiple Sclerosis and Related Disorders 80, 105132, 2023 | 1 | 2023 |
| OA-42 Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma treated on earlier total therapy protocols S Al Hadidi, O Ababneh, C Schinke, S Thanendrarajan, C Bailey, G Tricot, ... Clinical Lymphoma Myeloma and Leukemia 23, S25-S26, 2023 | 1 | 2023 |
| Is It Prime Time for Perioperative Therapy in Patients With Resectable Non–Small-Cell Lung Cancer? B El Osta, O Ababneh JCO Oncology Practice 19 (9), 685-687, 2023 | 1 | 2023 |
| The impact of IDH and NAT2 gene polymorphisms in acute myeloid leukemia risk and overall survival in an Arab population: A case-control study SM Al-Khatib, O Ababneh, H Abushukair, N Abdo, LN Al-Eitan Plos one 18 (7), e0289014, 2023 | 1 | 2023 |
| Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB. S Al Hadidi, OE Ababneh, CD Schinke, S Thanendrarajan, C Bailey, ... Journal of Clinical Oncology 41 (16_suppl), e20053-e20053, 2023 | 1 | 2023 |
| Variability of definition of high‐risk multiple myeloma across phase III clinical trials FJ Abu Za'nouneh, O Ababneh, C Schinke, S Thanendrarajan, M Zangari, ... EJHaem 4 (2), 454-458, 2023 | 1 | 2023 |
| The Use and Reporting of Cytogenetics in Phase III Multiple Myeloma Clinical Trials O Ababneh, FJ Abu Za'nouneh, C Schinke, S Thanendrarajan, M Zangari, ... Blood 140 (Supplement 1), 12532-12533, 2022 | 1 | 2022 |
| EP08. 02-121 the landscape of anti-neoplastic drugs for malignant pleural effusion in non-small cell lung cancer: a systematic review of clinical trials O Ababneh, Y Ahmed, S Syaj, Z Hatamleh, S Saleh, A Zaitoun, M Akhdar, ... Journal of Thoracic Oncology 17 (9), S459-S460, 2022 | 1 | 2022 |
| Pathological response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer (NSCLC): A systematic review and meta-analysis. S Syaj, M Akhdar, OE Ababneh, S Hamouri Journal of Clinical Oncology 40 (16_suppl), e20582-e20582, 2022 | 1 | 2022 |
| The predictive role of TNF-related genes in patients receiving immune checkpoint inhibitors OE Ababneh, S Kato, D Nishizaki, H Miyashita, S Lee, M Nesline, S Pabla, ... Cancer Research 84 (6_Supplement), 6393-6393, 2024 | | 2024 |
